List of Excipients in API tocilizumab
✉ Email this page to a colleague
Detailed excipient profiles for tocilizumab
Excipient focus: ARGININE
tocilizumab drug variants containing ARGININE
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing ARGININE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
Excipient focus: ARGININE HYDROCHLORIDE
tocilizumab drug variants containing ARGININE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing ARGININE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE
tocilizumab drug variants containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE HYDROCHLORIDE MONOHYDRATE
tocilizumab drug variants containing HISTIDINE HYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing HISTIDINE HYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
tocilizumab drug variants containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
tocilizumab drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTIC ACID, L-
tocilizumab drug variants containing LACTIC ACID, L-
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing LACTIC ACID, L-
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
tocilizumab drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM CHLORIDE
tocilizumab drug variants containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing SODIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
tocilizumab drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE
tocilizumab drug variants containing SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
tocilizumab drug variants containing SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
tocilizumab drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
tocilizumab drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Biogen MA Inc | tocilizumab | 64406-022 |
| Biogen Inc | tocilizumab | 64406-023 |
| Organon LLC | tocilizumab | 78206-200 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-586 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-590 |
| Fresenius Kabi USA LLC | tocilizumab-aazg | 65219-598 |
| >Company | >Ingredient | >NDC |
tocilizumab drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Genentech Inc | tocilizumab | 50242-135 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
